{"transactions":[{"id":4634360,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-10-03T00:10:06.000Z","date":"2026-09-30","kind":"exercise","planned":true,"acquired":false,"shares":5312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vests in 48 equal monthly installments following January 16, 2023, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":25235,"derivative":{"exercise_price":12.17,"expiration_date":"2033-01-15","underlying":"Common Stock","underlying_shares":5312},"source":{"system":"sec-edgar","filing":"0001104659-26-113279","document":"tm2626857-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926113279/tm2626857-1_4seq1.xml","form_type":"4"}},{"id":4634359,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-10-03T00:10:06.000Z","date":"2026-09-30","kind":"exercise","planned":true,"acquired":false,"shares":15650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option is fully vested."}],"balance_after":51150,"derivative":{"exercise_price":19.19,"expiration_date":"2032-04-17","underlying":"Common Stock","underlying_shares":15650},"source":{"system":"sec-edgar","filing":"0001104659-26-113279","document":"tm2626857-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926113279/tm2626857-1_4seq1.xml","form_type":"4"}},{"id":4634358,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-10-03T00:10:06.000Z","date":"2026-09-30","kind":"exercise","planned":true,"acquired":false,"shares":28438,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests in 48 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":49562,"derivative":{"exercise_price":23.42,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":28438},"source":{"system":"sec-edgar","filing":"0001104659-26-113279","document":"tm2626857-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926113279/tm2626857-1_4seq1.xml","form_type":"4"}},{"id":4634357,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-10-03T00:10:06.000Z","date":"2026-09-30","kind":"exercise","planned":true,"acquired":false,"shares":9229,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests in 48 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":29291,"derivative":{"exercise_price":38.98,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":9229},"source":{"system":"sec-edgar","filing":"0001104659-26-113279","document":"tm2626857-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926113279/tm2626857-1_4seq1.xml","form_type":"4"}},{"id":4634356,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-03T00:10:06.000Z","date":"2026-09-30","kind":"sale","planned":true,"acquired":false,"shares":46034,"price":141.78,"value":6526700.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $140.16 to $143.45. Upon request by the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":59003,"source":{"system":"sec-edgar","filing":"0001104659-26-113279","document":"tm2626857-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926113279/tm2626857-1_4seq1.xml","form_type":"4"}},{"id":4634355,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-03T00:10:06.000Z","date":"2026-09-30","kind":"sale","planned":true,"acquired":false,"shares":12595,"price":141.77,"value":1785593.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $140.21 to $143.31. Upon request by the staff of the U.S. Securities and Exchange Commission (the \"SEC\"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":105037,"source":{"system":"sec-edgar","filing":"0001104659-26-113279","document":"tm2626857-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926113279/tm2626857-1_4seq1.xml","form_type":"4"}},{"id":4634354,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-03T00:10:06.000Z","date":"2026-09-30","kind":"exercise","planned":true,"acquired":true,"shares":5312,"price":12.17,"value":64647.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."}],"balance_after":117632,"source":{"system":"sec-edgar","filing":"0001104659-26-113279","document":"tm2626857-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926113279/tm2626857-1_4seq1.xml","form_type":"4"}},{"id":4634353,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-03T00:10:06.000Z","date":"2026-09-30","kind":"exercise","planned":true,"acquired":true,"shares":15650,"price":19.19,"value":300323.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."}],"balance_after":112320,"source":{"system":"sec-edgar","filing":"0001104659-26-113279","document":"tm2626857-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926113279/tm2626857-1_4seq1.xml","form_type":"4"}},{"id":4634352,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-03T00:10:06.000Z","date":"2026-09-30","kind":"exercise","planned":true,"acquired":true,"shares":28438,"price":23.42,"value":666017.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."}],"balance_after":96670,"source":{"system":"sec-edgar","filing":"0001104659-26-113279","document":"tm2626857-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926113279/tm2626857-1_4seq1.xml","form_type":"4"}},{"id":4634351,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-03T00:10:06.000Z","date":"2026-09-30","kind":"exercise","planned":true,"acquired":true,"shares":9229,"price":38.98,"value":359746.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."}],"balance_after":68232,"source":{"system":"sec-edgar","filing":"0001104659-26-113279","document":"tm2626857-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926113279/tm2626857-1_4seq1.xml","form_type":"4"}},{"id":4615533,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-09-11T01:17:30.000Z","date":"2026-09-10","kind":"exercise","planned":true,"acquired":false,"shares":7278,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options."}],"balance_after":0,"derivative":{"exercise_price":21.58,"expiration_date":"2026-10-11","underlying":"Common Stock","underlying_shares":7278},"source":{"system":"sec-edgar","filing":"0001104659-26-106831","document":"tm2625158-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926106831/tm2625158-1_4seq1.xml","form_type":"4"}},{"id":4615532,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-09-11T01:17:30.000Z","date":"2026-09-09","kind":"exercise","planned":true,"acquired":false,"shares":63548,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options."}],"balance_after":7278,"derivative":{"exercise_price":21.58,"expiration_date":"2026-10-11","underlying":"Common Stock","underlying_shares":63548},"source":{"system":"sec-edgar","filing":"0001104659-26-106831","document":"tm2625158-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926106831/tm2625158-1_4seq1.xml","form_type":"4"}},{"id":4615531,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-09-11T01:17:30.000Z","date":"2026-09-08","kind":"exercise","planned":true,"acquired":false,"shares":54174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options."}],"balance_after":70826,"derivative":{"exercise_price":21.58,"expiration_date":"2026-10-11","underlying":"Common Stock","underlying_shares":54174},"source":{"system":"sec-edgar","filing":"0001104659-26-106831","document":"tm2625158-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926106831/tm2625158-1_4seq1.xml","form_type":"4"}},{"id":4615530,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T01:17:30.000Z","date":"2026-09-10","kind":"sale","planned":true,"acquired":false,"shares":7278,"price":144.1,"value":1048759.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $142.51 to $145.19. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":522968,"source":{"system":"sec-edgar","filing":"0001104659-26-106831","document":"tm2625158-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926106831/tm2625158-1_4seq1.xml","form_type":"4"}},{"id":4615529,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T01:17:30.000Z","date":"2026-09-10","kind":"exercise","planned":true,"acquired":true,"shares":7278,"price":21.58,"value":157059.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options."}],"balance_after":530246,"source":{"system":"sec-edgar","filing":"0001104659-26-106831","document":"tm2625158-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926106831/tm2625158-1_4seq1.xml","form_type":"4"}},{"id":4615528,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T01:17:30.000Z","date":"2026-09-09","kind":"sale","planned":true,"acquired":false,"shares":63548,"price":146.18,"value":9289446.64,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $144.49 to $151.27. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":522968,"source":{"system":"sec-edgar","filing":"0001104659-26-106831","document":"tm2625158-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926106831/tm2625158-1_4seq1.xml","form_type":"4"}},{"id":4615527,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T01:17:30.000Z","date":"2026-09-09","kind":"exercise","planned":true,"acquired":true,"shares":63548,"price":21.58,"value":1371365.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options."}],"balance_after":586516,"source":{"system":"sec-edgar","filing":"0001104659-26-106831","document":"tm2625158-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926106831/tm2625158-1_4seq1.xml","form_type":"4"}},{"id":4615526,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T01:17:30.000Z","date":"2026-09-08","kind":"sale","planned":true,"acquired":false,"shares":54174,"price":145.87,"value":7902361.38,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $142.00 to $147.29. Upon request by the staff of the U.S. Securities and Exchange Commission (the \"SEC\"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":522968,"source":{"system":"sec-edgar","filing":"0001104659-26-106831","document":"tm2625158-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926106831/tm2625158-1_4seq1.xml","form_type":"4"}},{"id":4615525,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T01:17:30.000Z","date":"2026-09-08","kind":"exercise","planned":true,"acquired":true,"shares":54174,"price":21.58,"value":1169074.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options."}],"balance_after":577142,"source":{"system":"sec-edgar","filing":"0001104659-26-106831","document":"tm2625158-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926106831/tm2625158-1_4seq1.xml","form_type":"4"}},{"id":3546694,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-08T21:14:07.000Z","date":"2026-09-03","kind":"gift","planned":false,"acquired":false,"shares":510,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction involves a bona fide gift of securities from the Reporting Person to relatives."}],"balance_after":522968,"source":{"system":"sec-edgar","filing":"0001104659-26-105955","document":"tm2624993-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926105955/tm2624993-1_4seq1.xml","form_type":"4"}},{"id":689598,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-08-12T22:43:08.000Z","date":"2026-08-11","kind":"exercise","planned":true,"acquired":false,"shares":34239,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options."}],"balance_after":125000,"derivative":{"exercise_price":21.58,"expiration_date":"2026-10-11","underlying":"Common Stock","underlying_shares":34239},"source":{"system":"sec-edgar","filing":"0001104659-26-095111","document":"tm2622954-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926095111/tm2622954-1_4seq1.xml","form_type":"4"}},{"id":689597,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-08-12T22:43:08.000Z","date":"2026-08-10","kind":"exercise","planned":true,"acquired":false,"shares":65761,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options."}],"balance_after":159239,"derivative":{"exercise_price":21.58,"expiration_date":"2026-10-11","underlying":"Common Stock","underlying_shares":65761},"source":{"system":"sec-edgar","filing":"0001104659-26-095111","document":"tm2622954-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926095111/tm2622954-1_4seq1.xml","form_type":"4"}},{"id":689596,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-08-12T22:43:08.000Z","date":"2026-08-11","kind":"sale","planned":true,"acquired":false,"shares":34239,"price":148.52,"value":5085176.28,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $147.64 to $151.30. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":523478,"source":{"system":"sec-edgar","filing":"0001104659-26-095111","document":"tm2622954-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926095111/tm2622954-1_4seq1.xml","form_type":"4"}},{"id":689595,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-08-12T22:43:08.000Z","date":"2026-08-11","kind":"exercise","planned":true,"acquired":true,"shares":34239,"price":21.58,"value":738877.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options."}],"balance_after":557717,"source":{"system":"sec-edgar","filing":"0001104659-26-095111","document":"tm2622954-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926095111/tm2622954-1_4seq1.xml","form_type":"4"}},{"id":689594,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-08-12T22:43:08.000Z","date":"2026-08-10","kind":"sale","planned":true,"acquired":false,"shares":65761,"price":149.11,"value":9805622.71,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $147.41 to $151.29. Upon request by the staff of the U.S. Securities and Exchange Commission (the \"SEC\"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":523478,"source":{"system":"sec-edgar","filing":"0001104659-26-095111","document":"tm2622954-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926095111/tm2622954-1_4seq1.xml","form_type":"4"}},{"id":689593,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-08-12T22:43:08.000Z","date":"2026-08-10","kind":"exercise","planned":true,"acquired":true,"shares":65761,"price":21.58,"value":1419122.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options."}],"balance_after":589239,"source":{"system":"sec-edgar","filing":"0001104659-26-095111","document":"tm2622954-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926095111/tm2622954-1_4seq1.xml","form_type":"4"}},{"id":726299,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-25T20:10:30.000Z","date":"2026-06-23","kind":"exercise","planned":true,"acquired":false,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":16.54,"expiration_date":"2030-05-27","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001104659-26-077761","document":"tm2618679-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926077761/tm2618679-1_4seq1.xml","form_type":"4"}},{"id":726298,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-25T20:10:30.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":9000,"price":117.94,"value":1061460.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $117.00 to $119.07. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":7825,"source":{"system":"sec-edgar","filing":"0001104659-26-077761","document":"tm2618679-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926077761/tm2618679-1_4seq1.xml","form_type":"4"}},{"id":726297,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-25T20:10:30.000Z","date":"2026-06-23","kind":"exercise","planned":true,"acquired":true,"shares":9000,"price":16.54,"value":148860.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 27, 2026."}],"balance_after":16825,"source":{"system":"sec-edgar","filing":"0001104659-26-077761","document":"tm2618679-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926077761/tm2618679-1_4seq1.xml","form_type":"4"}},{"id":741483,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-11T23:06:39.000Z","date":"2026-06-10","kind":"exercise","planned":true,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options are fully vested."}],"balance_after":9000,"derivative":{"exercise_price":16.54,"expiration_date":"2030-05-27","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001104659-26-073049","document":"tm2617708-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926073049/tm2617708-1_4seq1.xml","form_type":"4"}},{"id":741482,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-11T23:06:39.000Z","date":"2026-06-10","kind":"exercise","planned":true,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":11.8,"expiration_date":"2029-06-06","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001104659-26-073049","document":"tm2617708-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926073049/tm2617708-1_4seq1.xml","form_type":"4"}},{"id":741481,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-11T23:06:39.000Z","date":"2026-06-10","kind":"sale","planned":true,"acquired":false,"shares":9000,"price":107.68,"value":969120.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $107.02 to $108.00. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":7825,"source":{"system":"sec-edgar","filing":"0001104659-26-073049","document":"tm2617708-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926073049/tm2617708-1_4seq1.xml","form_type":"4"}},{"id":741480,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-11T23:06:39.000Z","date":"2026-06-10","kind":"exercise","planned":true,"acquired":true,"shares":6000,"price":16.54,"value":99240.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 27, 2026."}],"balance_after":16825,"source":{"system":"sec-edgar","filing":"0001104659-26-073049","document":"tm2617708-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926073049/tm2617708-1_4seq1.xml","form_type":"4"}},{"id":741479,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-11T23:06:39.000Z","date":"2026-06-10","kind":"exercise","planned":true,"acquired":true,"shares":3000,"price":11.8,"value":35400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 27, 2026."}],"balance_after":10825,"source":{"system":"sec-edgar","filing":"0001104659-26-073049","document":"tm2617708-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926073049/tm2617708-1_4seq1.xml","form_type":"4"}},{"id":756904,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-01T22:31:22.000Z","date":"2026-05-29","kind":"exercise","planned":true,"acquired":false,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These stock options are fully vested."}],"balance_after":3000,"derivative":{"exercise_price":11.8,"expiration_date":"2029-06-06","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001104659-26-069047","document":"tm2616565-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926069047/tm2616565-1_4seq1.xml","form_type":"4"}},{"id":756903,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-01T22:31:22.000Z","date":"2026-05-29","kind":"sale","planned":true,"acquired":false,"shares":9000,"price":99.64,"value":896760.0,"ownership":{"direct":true},"balance_after":7825,"source":{"system":"sec-edgar","filing":"0001104659-26-069047","document":"tm2616565-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926069047/tm2616565-1_4seq1.xml","form_type":"4"}},{"id":756902,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-01T22:31:22.000Z","date":"2026-05-29","kind":"exercise","planned":true,"acquired":true,"shares":9000,"price":11.8,"value":106200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 27, 2026."}],"balance_after":16825,"source":{"system":"sec-edgar","filing":"0001104659-26-069047","document":"tm2616565-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926069047/tm2616565-1_4seq1.xml","form_type":"4"}},{"id":779637,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-05-15T00:06:46.000Z","date":"2026-05-12","kind":"exercise","planned":true,"acquired":false,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options are fully vested and will expire on October 11, 2026."}],"balance_after":225000,"derivative":{"exercise_price":21.58,"expiration_date":"2026-10-11","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001104659-26-061476","document":"tm2614674-1_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926061476/tm2614674-1_4aseq1.xml","form_type":"4/A","original_submission_date":"2026-05-12"}},{"id":779636,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-05-15T00:06:46.000Z","date":"2026-05-12","kind":"sale","planned":true,"acquired":false,"shares":75000,"price":100.12,"value":7509000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $98.83 to $103.50. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":523478,"source":{"system":"sec-edgar","filing":"0001104659-26-061476","document":"tm2614674-1_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926061476/tm2614674-1_4aseq1.xml","form_type":"4/A","original_submission_date":"2026-05-12"}},{"id":779635,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-05-15T00:06:46.000Z","date":"2026-05-12","kind":"exercise","planned":true,"acquired":true,"shares":75000,"price":21.58,"value":1618500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 Amendment is being filed to clarify that the transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026 and to check the appropriate box which appeared unchecked on the original Form 4 filing."}],"balance_after":598478,"source":{"system":"sec-edgar","filing":"0001104659-26-061476","document":"tm2614674-1_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926061476/tm2614674-1_4aseq1.xml","form_type":"4/A","original_submission_date":"2026-05-12"}},{"id":783010,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-05-12T23:28:00.000Z","date":"2026-05-12","kind":"exercise","planned":false,"acquired":false,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These stock options are fully vested and will expire on October 11, 2026."}],"balance_after":225000,"derivative":{"exercise_price":21.58,"expiration_date":"2026-10-11","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001104659-26-059591","document":"tm2614444-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926059591/tm2614444-1_4seq1.xml","form_type":"4"}},{"id":783009,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-05-12T23:28:00.000Z","date":"2026-05-12","kind":"sale","planned":false,"acquired":false,"shares":75000,"price":100.12,"value":7509000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $98.83 to $103.50. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":523478,"source":{"system":"sec-edgar","filing":"0001104659-26-059591","document":"tm2614444-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926059591/tm2614444-1_4seq1.xml","form_type":"4"}},{"id":783008,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-05-12T23:28:00.000Z","date":"2026-05-12","kind":"exercise","planned":false,"acquired":true,"shares":75000,"price":21.58,"value":1618500.0,"ownership":{"direct":true},"balance_after":598478,"source":{"system":"sec-edgar","filing":"0001104659-26-059591","document":"tm2614444-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926059591/tm2614444-1_4seq1.xml","form_type":"4"}},{"id":784586,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":19370,"kind":"person","name":"Giraudo Bryan","position":1,"cik":"0001740847","reported_name":"Giraudo Bryan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-12T00:25:57.000Z","date":"2026-05-07","kind":"exercise","planned":false,"acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":6.98,"expiration_date":"2028-05-28","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001104659-26-058860","document":"tm2614277-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926058860/tm2614277-1_4seq1.xml","form_type":"4"}},{"id":784585,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":19370,"kind":"person","name":"Giraudo Bryan","position":1,"cik":"0001740847","reported_name":"Giraudo Bryan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-12T00:25:57.000Z","date":"2026-05-07","kind":"exercise","planned":false,"acquired":false,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":6.45,"expiration_date":"2028-05-14","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001104659-26-058860","document":"tm2614277-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926058860/tm2614277-1_4seq1.xml","form_type":"4"}},{"id":784584,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":19370,"kind":"person","name":"Giraudo Bryan","position":1,"cik":"0001740847","reported_name":"Giraudo Bryan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-12T00:25:57.000Z","date":"2026-05-08","kind":"sale","planned":false,"acquired":false,"shares":5130,"price":100,"value":513000.0,"ownership":{"direct":true},"balance_after":12695,"source":{"system":"sec-edgar","filing":"0001104659-26-058860","document":"tm2614277-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926058860/tm2614277-1_4seq1.xml","form_type":"4"}},{"id":784583,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":19370,"kind":"person","name":"Giraudo Bryan","position":1,"cik":"0001740847","reported_name":"Giraudo Bryan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-12T00:25:57.000Z","date":"2026-05-08","kind":"sale","planned":false,"acquired":false,"shares":6000,"price":100,"value":600000.0,"ownership":{"direct":false,"nature":"By Bryan & Courtney Giraudo Trust"},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-058860","document":"tm2614277-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926058860/tm2614277-1_4seq1.xml","form_type":"4"}},{"id":784582,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":19370,"kind":"person","name":"Giraudo Bryan","position":1,"cik":"0001740847","reported_name":"Giraudo Bryan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-12T00:25:57.000Z","date":"2026-05-07","kind":"sale","planned":false,"acquired":false,"shares":12000,"price":100.07,"value":1200840.0,"ownership":{"direct":false,"nature":"By Bryan & Courtney Giraudo Trust"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects 10,000 shares of common stock that were previously held directly by the Reporting Person and which were transferred to the Bryan & Courtney Giraudo Trust."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001104659-26-058860","document":"tm2614277-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926058860/tm2614277-1_4seq1.xml","form_type":"4"}},{"id":784581,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":19370,"kind":"person","name":"Giraudo Bryan","position":1,"cik":"0001740847","reported_name":"Giraudo Bryan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-12T00:25:57.000Z","date":"2026-05-07","kind":"sale","planned":false,"acquired":false,"shares":36000,"price":100.14,"value":3605040.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $98.69 to $104.67. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":27825,"source":{"system":"sec-edgar","filing":"0001104659-26-058860","document":"tm2614277-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926058860/tm2614277-1_4seq1.xml","form_type":"4"}},{"id":784580,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":19370,"kind":"person","name":"Giraudo Bryan","position":1,"cik":"0001740847","reported_name":"Giraudo Bryan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-12T00:25:57.000Z","date":"2026-05-07","kind":"exercise","planned":false,"acquired":true,"shares":12000,"price":6.98,"value":83760.0,"ownership":{"direct":true},"balance_after":43825,"source":{"system":"sec-edgar","filing":"0001104659-26-058860","document":"tm2614277-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926058860/tm2614277-1_4seq1.xml","form_type":"4"}},{"id":784579,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":19370,"kind":"person","name":"Giraudo Bryan","position":1,"cik":"0001740847","reported_name":"Giraudo Bryan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-12T00:25:57.000Z","date":"2026-05-07","kind":"exercise","planned":false,"acquired":true,"shares":24000,"price":6.45,"value":154800.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects 10,000 shares of common stock that were previously held directly by the Reporting Person and which were transferred to the Bryan & Courtney Giraudo Trust."}],"balance_after":31825,"source":{"system":"sec-edgar","filing":"0001104659-26-058860","document":"tm2614277-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926058860/tm2614277-1_4seq1.xml","form_type":"4"}},{"id":801169,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-04-24T20:10:16.000Z","date":"2026-04-23","kind":"gift","planned":false,"acquired":false,"shares":1460,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction involves a bona fide gift of securities from the Reporting Person to family and friends."}],"balance_after":523478,"source":{"system":"sec-edgar","filing":"0001104659-26-048572","document":"tm2612651-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926048572/tm2612651-1_4seq1.xml","form_type":"4"}},{"id":803795,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-21T20:58:35.000Z","date":"2026-04-20","kind":"sale","planned":false,"acquired":false,"shares":1750,"price":105.47,"value":184572.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units."}],"balance_after":59003,"source":{"system":"sec-edgar","filing":"0001104659-26-046110","document":"tm2612380-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926046110/tm2612380-2_4seq1.xml","form_type":"4"}},{"id":826284,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-27T23:36:20.000Z","date":"2026-03-26","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option was granted to the Reporting Person on November 7, 2022, one quarter vested on November 7, 2023 and the remaining three quarters vest in equal monthly installments through November 7, 2026, subject to the Reporting Person's continuous service to the Issuer."}],"balance_after":50971,"derivative":{"exercise_price":8.04,"expiration_date":"2032-11-15","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-26-036319","document":"tm2610129-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926036319/tm2610129-3_4seq1.xml","form_type":"4"}},{"id":826283,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-27T23:36:20.000Z","date":"2026-03-26","kind":"sale","planned":false,"acquired":false,"shares":15000,"price":104.79,"value":1571850.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $103.99 to $105.54. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":84115,"source":{"system":"sec-edgar","filing":"0001104659-26-036319","document":"tm2610129-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926036319/tm2610129-3_4seq1.xml","form_type":"4"}},{"id":826282,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-27T23:36:20.000Z","date":"2026-03-26","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":8.04,"value":120600.0,"ownership":{"direct":true},"balance_after":99115,"source":{"system":"sec-edgar","filing":"0001104659-26-036319","document":"tm2610129-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926036319/tm2610129-3_4seq1.xml","form_type":"4"}},{"id":826281,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55588,"kind":"person","name":"SELICK HAROLD E","position":1,"cik":"0001287233","reported_name":"SELICK HAROLD E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-27T23:34:29.000Z","date":"2026-03-26","kind":"exercise","planned":false,"acquired":false,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":12.88,"expiration_date":"2026-09-13","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001104659-26-036318","document":"tm2610129-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926036318/tm2610129-2_4seq1.xml","form_type":"4"}},{"id":826280,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55588,"kind":"person","name":"SELICK HAROLD E","position":1,"cik":"0001287233","reported_name":"SELICK HAROLD E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-27T23:34:29.000Z","date":"2026-03-26","kind":"sale","planned":false,"acquired":false,"shares":24000,"price":105,"value":2520000.0,"ownership":{"direct":true},"balance_after":60845,"source":{"system":"sec-edgar","filing":"0001104659-26-036318","document":"tm2610129-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926036318/tm2610129-2_4seq1.xml","form_type":"4"}},{"id":826279,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55588,"kind":"person","name":"SELICK HAROLD E","position":1,"cik":"0001287233","reported_name":"SELICK HAROLD E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-27T23:34:29.000Z","date":"2026-03-26","kind":"exercise","planned":false,"acquired":true,"shares":24000,"price":12.88,"value":309120.0,"ownership":{"direct":true},"balance_after":84845,"source":{"system":"sec-edgar","filing":"0001104659-26-036318","document":"tm2610129-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926036318/tm2610129-2_4seq1.xml","form_type":"4"}},{"id":826512,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-27T23:33:56.000Z","date":"2026-03-26","kind":"exercise","planned":false,"acquired":false,"shares":5265,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option was granted to the Reporting Person on January 16, 2023 and vests in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":13282,"derivative":{"exercise_price":12.17,"expiration_date":"2033-01-15","underlying":"Common Stock","underlying_shares":5265},"source":{"system":"sec-edgar","filing":"0001104659-26-036317","document":"tm2610129-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926036317/tm2610129-1_4seq1.xml","form_type":"4"}},{"id":826511,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-27T23:33:56.000Z","date":"2026-03-26","kind":"exercise","planned":false,"acquired":false,"shares":19500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option was granted to the Reporting Person on April 18, 2022, one quarter vested on April 18, 2023 and the remaining three quarters vest in equal monthly installments through April 18, 2026, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":31300,"derivative":{"exercise_price":19.19,"expiration_date":"2032-04-18","underlying":"Common Stock","underlying_shares":19500},"source":{"system":"sec-edgar","filing":"0001104659-26-036317","document":"tm2610129-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926036317/tm2610129-1_4seq1.xml","form_type":"4"}},{"id":826510,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-27T23:33:56.000Z","date":"2026-03-26","kind":"sale","planned":false,"acquired":false,"shares":24765,"price":104.24,"value":2581503.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $104.00 to $104.465. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":60753,"source":{"system":"sec-edgar","filing":"0001104659-26-036317","document":"tm2610129-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926036317/tm2610129-1_4seq1.xml","form_type":"4"}},{"id":826509,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-27T23:33:56.000Z","date":"2026-03-26","kind":"exercise","planned":false,"acquired":true,"shares":5265,"price":12.17,"value":64075.05,"ownership":{"direct":true},"balance_after":85518,"source":{"system":"sec-edgar","filing":"0001104659-26-036317","document":"tm2610129-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926036317/tm2610129-1_4seq1.xml","form_type":"4"}},{"id":826508,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-27T23:33:56.000Z","date":"2026-03-26","kind":"exercise","planned":false,"acquired":true,"shares":19500,"price":19.19,"value":374205.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes an aggregate of 433 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2026."}],"balance_after":80253,"source":{"system":"sec-edgar","filing":"0001104659-26-036317","document":"tm2610129-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926036317/tm2610129-1_4seq1.xml","form_type":"4"}},{"id":828472,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-25T23:23:16.000Z","date":"2026-03-25","kind":"exercise","planned":false,"acquired":false,"shares":54641,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.58,"expiration_date":"2028-08-14","underlying":"Common Stock","underlying_shares":54641},"source":{"system":"sec-edgar","filing":"0001104659-26-034736","document":"tm269861-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926034736/tm269861-1_4seq1.xml","form_type":"4"}},{"id":828471,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-25T23:23:16.000Z","date":"2026-03-24","kind":"exercise","planned":false,"acquired":false,"shares":59,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options are fully vested."}],"balance_after":54641,"derivative":{"exercise_price":8.58,"expiration_date":"2028-08-14","underlying":"Common Stock","underlying_shares":59},"source":{"system":"sec-edgar","filing":"0001104659-26-034736","document":"tm269861-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926034736/tm269861-1_4seq1.xml","form_type":"4"}},{"id":828470,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-03-25T23:23:16.000Z","date":"2026-03-25","kind":"sale","planned":false,"acquired":false,"shares":54641,"price":101,"value":5518741.0,"ownership":{"direct":true},"balance_after":524938,"source":{"system":"sec-edgar","filing":"0001104659-26-034736","document":"tm269861-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926034736/tm269861-1_4seq1.xml","form_type":"4"}},{"id":828469,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-03-25T23:23:16.000Z","date":"2026-03-25","kind":"exercise","planned":false,"acquired":true,"shares":54641,"price":8.58,"value":468819.78,"ownership":{"direct":true},"balance_after":579579,"source":{"system":"sec-edgar","filing":"0001104659-26-034736","document":"tm269861-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926034736/tm269861-1_4seq1.xml","form_type":"4"}},{"id":828468,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-03-25T23:23:16.000Z","date":"2026-03-24","kind":"sale","planned":false,"acquired":false,"shares":59,"price":101,"value":5959.0,"ownership":{"direct":true},"balance_after":524938,"source":{"system":"sec-edgar","filing":"0001104659-26-034736","document":"tm269861-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926034736/tm269861-1_4seq1.xml","form_type":"4"}},{"id":828467,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-03-25T23:23:16.000Z","date":"2026-03-24","kind":"exercise","planned":false,"acquired":true,"shares":59,"price":8.58,"value":506.22,"ownership":{"direct":true},"balance_after":524997,"source":{"system":"sec-edgar","filing":"0001104659-26-034736","document":"tm269861-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926034736/tm269861-1_4seq1.xml","form_type":"4"}},{"id":828466,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-03-25T23:23:16.000Z","date":"2026-03-23","kind":"gift","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction involves a bona fide gift of securities from the Reporting Person to relatives."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an aggregate of 433 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2026."}],"balance_after":524938,"source":{"system":"sec-edgar","filing":"0001104659-26-034736","document":"tm269861-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926034736/tm269861-1_4seq1.xml","form_type":"4"}},{"id":896446,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-18T23:12:56.000Z","date":"2026-02-17","kind":"exercise","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These stock options are fully vested."}],"balance_after":6000,"derivative":{"exercise_price":10.84,"expiration_date":"2027-06-15","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001104659-26-017176","document":"tm266755-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926017176/tm266755-1_4seq1.xml","form_type":"4"}},{"id":896445,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-18T23:12:56.000Z","date":"2026-02-17","kind":"sale","planned":false,"acquired":false,"shares":18000,"price":82.42,"value":1483560.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $81.47 to $83.12. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":7825,"source":{"system":"sec-edgar","filing":"0001104659-26-017176","document":"tm266755-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926017176/tm266755-1_4seq1.xml","form_type":"4"}},{"id":896444,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-18T23:12:56.000Z","date":"2026-02-17","kind":"exercise","planned":false,"acquired":true,"shares":18000,"price":10.84,"value":195120.0,"ownership":{"direct":true},"balance_after":25825,"source":{"system":"sec-edgar","filing":"0001104659-26-017176","document":"tm266755-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926017176/tm266755-1_4seq1.xml","form_type":"4"}},{"id":915903,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-06T21:38:54.000Z","date":"2026-02-06","kind":"exercise","planned":false,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These stock options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.31,"expiration_date":"2032-05-25","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-26-011575","document":"tm265544-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926011575/tm265544-1_4seq1.xml","form_type":"4"}},{"id":915902,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-06T21:38:54.000Z","date":"2026-02-06","kind":"sale","planned":false,"acquired":false,"shares":20000,"price":83.68,"value":1673600.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $83.65 to $83.87. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":7825,"source":{"system":"sec-edgar","filing":"0001104659-26-011575","document":"tm265544-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926011575/tm265544-1_4seq1.xml","form_type":"4"}},{"id":915901,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-06T21:38:54.000Z","date":"2026-02-06","kind":"exercise","planned":false,"acquired":true,"shares":20000,"price":8.31,"value":166200.0,"ownership":{"direct":true},"balance_after":27825,"source":{"system":"sec-edgar","filing":"0001104659-26-011575","document":"tm265544-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926011575/tm265544-1_4seq1.xml","form_type":"4"}},{"id":930273,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-28T02:21:26.000Z","date":"2026-01-27","kind":"exercise","planned":false,"acquired":false,"shares":4068,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"These stock options are fully vested and will expire on October 11, 2026."}],"balance_after":300000,"derivative":{"exercise_price":21.58,"expiration_date":"2026-10-11","underlying":"Common Stock","underlying_shares":4068},"source":{"system":"sec-edgar","filing":"0001104659-26-007129","document":"tm264253-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926007129/tm264253-3_4seq1.xml","form_type":"4"}},{"id":930272,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-28T02:21:26.000Z","date":"2026-01-26","kind":"exercise","planned":false,"acquired":false,"shares":14205,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"These stock options are fully vested and will expire on October 11, 2026."}],"balance_after":304068,"derivative":{"exercise_price":21.58,"expiration_date":"2026-10-11","underlying":"Common Stock","underlying_shares":14205},"source":{"system":"sec-edgar","filing":"0001104659-26-007129","document":"tm264253-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926007129/tm264253-3_4seq1.xml","form_type":"4"}},{"id":930271,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-28T02:21:26.000Z","date":"2026-01-26","kind":"exercise","planned":false,"acquired":false,"shares":10685,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These stock options are fully vested and will expire on April 29, 2026."}],"balance_after":0,"derivative":{"exercise_price":4.21,"expiration_date":"2026-04-29","underlying":"Common Stock","underlying_shares":10685},"source":{"system":"sec-edgar","filing":"0001104659-26-007129","document":"tm264253-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926007129/tm264253-3_4seq1.xml","form_type":"4"}},{"id":930270,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-28T02:21:26.000Z","date":"2026-01-23","kind":"exercise","planned":false,"acquired":false,"shares":19315,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These stock options are fully vested and will expire on April 29, 2026."}],"balance_after":10685,"derivative":{"exercise_price":4.21,"expiration_date":"2026-04-29","underlying":"Common Stock","underlying_shares":19315},"source":{"system":"sec-edgar","filing":"0001104659-26-007129","document":"tm264253-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926007129/tm264253-3_4seq1.xml","form_type":"4"}},{"id":930269,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-28T02:21:26.000Z","date":"2026-01-27","kind":"sale","planned":false,"acquired":false,"shares":4068,"price":83.19,"value":338416.92,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $83.06 to $83.59. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":574505,"source":{"system":"sec-edgar","filing":"0001104659-26-007129","document":"tm264253-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926007129/tm264253-3_4seq1.xml","form_type":"4"}},{"id":930268,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-28T02:21:26.000Z","date":"2026-01-27","kind":"exercise","planned":false,"acquired":true,"shares":4068,"price":21.58,"value":87787.44,"ownership":{"direct":true},"balance_after":578573,"source":{"system":"sec-edgar","filing":"0001104659-26-007129","document":"tm264253-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926007129/tm264253-3_4seq1.xml","form_type":"4"}},{"id":930267,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-28T02:21:26.000Z","date":"2026-01-26","kind":"sale","planned":false,"acquired":false,"shares":14205,"price":84.05,"value":1193930.25,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $84 to $84.075. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":574505,"source":{"system":"sec-edgar","filing":"0001104659-26-007129","document":"tm264253-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926007129/tm264253-3_4seq1.xml","form_type":"4"}},{"id":930266,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-28T02:21:26.000Z","date":"2026-01-26","kind":"exercise","planned":false,"acquired":true,"shares":14205,"price":21.58,"value":306543.9,"ownership":{"direct":true},"balance_after":588710,"source":{"system":"sec-edgar","filing":"0001104659-26-007129","document":"tm264253-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926007129/tm264253-3_4seq1.xml","form_type":"4"}},{"id":930265,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-28T02:21:26.000Z","date":"2026-01-26","kind":"sale","planned":false,"acquired":false,"shares":10685,"price":84,"value":897540.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $84 to $84.095. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":574505,"source":{"system":"sec-edgar","filing":"0001104659-26-007129","document":"tm264253-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926007129/tm264253-3_4seq1.xml","form_type":"4"}},{"id":930264,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-28T02:21:26.000Z","date":"2026-01-26","kind":"exercise","planned":false,"acquired":true,"shares":10685,"price":4.21,"value":44983.85,"ownership":{"direct":true},"balance_after":585190,"source":{"system":"sec-edgar","filing":"0001104659-26-007129","document":"tm264253-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926007129/tm264253-3_4seq1.xml","form_type":"4"}},{"id":930263,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-28T02:21:26.000Z","date":"2026-01-23","kind":"sale","planned":false,"acquired":false,"shares":19315,"price":84.59,"value":1633855.85,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $84.41 to $84.64. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":574505,"source":{"system":"sec-edgar","filing":"0001104659-26-007129","document":"tm264253-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926007129/tm264253-3_4seq1.xml","form_type":"4"}},{"id":930262,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-28T02:21:26.000Z","date":"2026-01-23","kind":"exercise","planned":false,"acquired":true,"shares":19315,"price":4.21,"value":81316.15,"ownership":{"direct":true},"balance_after":593820,"source":{"system":"sec-edgar","filing":"0001104659-26-007129","document":"tm264253-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926007129/tm264253-3_4seq1.xml","form_type":"4"}},{"id":930261,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-28T02:21:26.000Z","date":"2026-01-23","kind":"gift","planned":false,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 23, 2026, the Reporting Person made a charitable donation of 6,000 shares of common stock to a donor-advised fund, which will use the gifted shares for charitable purposes."}],"balance_after":574505,"source":{"system":"sec-edgar","filing":"0001104659-26-007129","document":"tm264253-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926007129/tm264253-3_4seq1.xml","form_type":"4"}},{"id":930140,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-28T02:20:42.000Z","date":"2026-01-27","kind":"exercise","planned":false,"acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option was granted to the Reporting Person on January 16, 2023 and vests in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":18547,"derivative":{"exercise_price":12.17,"expiration_date":"2033-01-15","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001104659-26-007128","document":"tm264253-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926007128/tm264253-2_4seq1.xml","form_type":"4"}},{"id":930139,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-28T02:20:42.000Z","date":"2026-01-27","kind":"exercise","planned":false,"acquired":false,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option was granted to the Reporting Person on April 18, 2022, one quarter vested on April 18, 2023 and the remaining three quarters vest in equal monthly installments through April 18, 2026, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":50800,"derivative":{"exercise_price":19.19,"expiration_date":"2032-04-18","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001104659-26-007128","document":"tm264253-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926007128/tm264253-2_4seq1.xml","form_type":"4"}},{"id":930138,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-28T02:20:42.000Z","date":"2026-01-27","kind":"sale","planned":false,"acquired":false,"shares":18203,"price":83.14,"value":1513397.42,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $82.80 to $83.595. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":60320,"source":{"system":"sec-edgar","filing":"0001104659-26-007128","document":"tm264253-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926007128/tm264253-2_4seq1.xml","form_type":"4"}},{"id":930137,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-28T02:20:42.000Z","date":"2026-01-27","kind":"sale","planned":false,"acquired":false,"shares":28000,"price":83.13,"value":2327640.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $82.77 to $83.595. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":78523,"source":{"system":"sec-edgar","filing":"0001104659-26-007128","document":"tm264253-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926007128/tm264253-2_4seq1.xml","form_type":"4"}},{"id":930136,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-28T02:20:42.000Z","date":"2026-01-27","kind":"exercise","planned":false,"acquired":true,"shares":12000,"price":12.17,"value":146040.0,"ownership":{"direct":true},"balance_after":106523,"source":{"system":"sec-edgar","filing":"0001104659-26-007128","document":"tm264253-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926007128/tm264253-2_4seq1.xml","form_type":"4"}},{"id":930135,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-28T02:20:42.000Z","date":"2026-01-27","kind":"exercise","planned":false,"acquired":true,"shares":16000,"price":19.19,"value":307040.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes an aggregate of 446 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2025."}],"balance_after":94523,"source":{"system":"sec-edgar","filing":"0001104659-26-007128","document":"tm264253-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926007128/tm264253-2_4seq1.xml","form_type":"4"}},{"id":929900,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-28T02:19:50.000Z","date":"2026-01-27","kind":"exercise","planned":false,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option represents a right to purchase a total of 127,500 shares of the Issuer's common stock, one quarter of which vested on November 7, 2023, with the remaining three quarters vesting in equal monthly installments through November 7, 2026, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":65971,"derivative":{"exercise_price":8.04,"expiration_date":"2032-11-15","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001104659-26-007127","document":"tm264253-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926007127/tm264253-1_4seq1.xml","form_type":"4"}},{"id":929899,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-28T02:19:50.000Z","date":"2026-01-26","kind":"exercise","planned":false,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option represents a right to purchase a total of 127,500 shares of the Issuer's common stock, one quarter of which vested on November 7, 2023, with the remaining three quarters vesting in equal monthly installments through November 7, 2026, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":70971,"derivative":{"exercise_price":8.04,"expiration_date":"2032-11-15","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001104659-26-007127","document":"tm264253-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926007127/tm264253-1_4seq1.xml","form_type":"4"}},{"id":929898,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-28T02:19:50.000Z","date":"2026-01-27","kind":"sale","planned":false,"acquired":false,"shares":5000,"price":82,"value":410000.0,"ownership":{"direct":true},"balance_after":84115,"source":{"system":"sec-edgar","filing":"0001104659-26-007127","document":"tm264253-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926007127/tm264253-1_4seq1.xml","form_type":"4"}},{"id":929897,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-28T02:19:50.000Z","date":"2026-01-27","kind":"exercise","planned":false,"acquired":true,"shares":5000,"price":8.04,"value":40200.0,"ownership":{"direct":true},"balance_after":89115,"source":{"system":"sec-edgar","filing":"0001104659-26-007127","document":"tm264253-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926007127/tm264253-1_4seq1.xml","form_type":"4"}}],"next_cursor":"2026-01-28T02:19:50.000000Z,929897"}